TABLE 3.

PI3K/AKT/mTOR inhibitors in cancers.

Compound	Target	Cancer	Clinical symptoms	Reference
Wortmannin	PI3K	Lung cancer and breast cancer and other solid tumors	Poor solubility, instability, and high toxicity	Ekman et al. (2012)
LY2994002	PI3K	Lung cancer and breast cancer and other solid tumors	Poor solubility, instability, and high toxicity	Ekman et al. (2012)
BKM120	PI3K	Gastric cancer	Well tolerated, high toxicity	Yang et al. (2018b)
PX-886	PI3K	Gastric cancer	Instability, and high toxicity	Yang et al. (2018a)
XL147	PI3K	Gastric cancer	Poor solubility, instability, and high toxicity	Gravina et al. (2016)
WX-037	PI3K	Gastric cancer		Haagensen et al. (2016)
BYL719	PI3K	Gastric cancer	Poor solubility, instability, and high toxicity	Juric et al. (2018)
GDC0032	PI3K	Gastric cancer		Juric et al. (2018)
P7170	PI3K/mTOR	Gastric cancer, lung cancer		Jalota-Badhwar et al. (2015)
BEZ235	PI3K/mTOR	Gastric cancer	Well tolerated, gastrointestinal toxicity	Kim et al. (2019)
XL765	PI3K/mTOR	Gastric cancer		Gravina et al. (2016)
GDC-0980	PI3K/mTOR	Gastric cancer, breast cancer	Poor solubility, instability, and high toxicity	Kim et al. (2019)
GDC-0941	PI3K/mTOR	Gastric cancer	Poor solubility, instability, and high toxicity	Ekman et al. (2012)
SF1126	PI3K/mTOR	Gastric cancer	Poor solubility, Instability, and high toxicity	Kim et al. (2019)
PF-05212384	PI3K/mTOR	Gastric cancer		Kim et al. (2019)
PF-4691502	PI3K/mTOR	Gastric cancer		Kim et al. (2019)
VS-558	PI3K/mTOR	Gastric cancer		Kim et al. (2019)
MK-2206	Allosteric AKT	Gastric cancer	Well tolerated, high toxicity	Hirai et al. (2010)
AZD5363	Catalytic AKT	Gastric cancer		Brown and Banerji (2017)
GSK690693	Catalytic AKT	Gastric cancer	Poor solubility, instability, and high toxicity	Brown and Banerji (2017)
Everolimus	mTOR	Breast cancer	Tends to have an infection, including bacterial, fungal, and viral infections, as well as reactivation of hepatitis B virus/increased incidence of fatigue, asthenia, and anorexia	Janku et al. (2014)